Get the Stockscreener App
15.16
2.13%
-0.33
After Hours:
15.17
0.010
+0.07%
Arcutis Biotherapeutics Inc stock is traded at $15.16, with a volume of 2.33M.
It is down -2.13% in the last 24 hours and up +14.76% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$15.49
Open:
$15.76
24h Volume:
2.33M
Relative Volume:
1.10
Market Cap:
$1.80B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-3.8673
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
+2.57%
1M Performance:
+14.76%
6M Performance:
+44.11%
1Y Performance:
+49.95%
1-Day Range:
$14.73
$16.09
1-Week Range:
$13.80
$16.09
52-Week Range:
$6.99
$16.20
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
15.16 | 1.80B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial Group - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% Following Analyst Upgrade - Defense World
Jefferies lifts Arcutis stock price target to $19, retains Buy rating - Investing.com Canada
Jefferies lifts Arcutis stock price target to $19, retains Buy rating By Investing.com - Investing.com South Africa
Hand Eczema Clinical and Non-Clinical Studies, Key Companies, - openPR
Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $18.00 - Defense World
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up - Simply Wall St
Arcutis Biotherapeutics announces new data from two posters at 2025 AAD - TipRanks
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting - The Manila Times
Arcutis Biotherapeutics Inc (ARQT) Unveils Promising Data on ZORYVE® Cream and Foam at AAD 2025 - GuruFocus.com
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic ... - The Bakersfield Californian
Breakthrough Phase 3 Results: New Treatment Shows 97% Success Rate in Major Skin Conditions - StockTitan
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average - Yahoo Finance
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN
Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherape - GuruFocus.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Seborrhoeic Dermatitis Clinical and Non-Clinical Studies, Key - openPR
Arcutis Biotherapeutics (ARQT) – Research Analysts’ Recent Ratings Updates - Defense World
Arcutis Biotherapeutics Inc Stock: Executives Sell Shares Following Strong Results - sharewise
Arcutis Biotherapeutics director sells $130,048 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics executive sells $49,407 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics executive sells $49,407 in stock - Investing.com India
Arcutis Biotherapeutics CEO Todd Watanabe sells $327,019 in stock - Investing.com
Arcutis Biotherapeutics’ general counsel Matsuda sells $42,520 in stock By Investing.com - Investing.com UK
Seborrhea Clinical and Non-Clinical Studies, Key Companies, - openPR
Arcutis Biotherapeutics director sells $130,048 in stock - Investing.com
Arcutis Biotherapeutics Shines in Earnings Call - TipRanks
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $15.00 - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Given New $21.00 Price Target at Mizuho - MarketBeat
Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT In - GuruFocus.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Posts Earnings Results, Beats Expectations By $0.19 EPS - MarketBeat
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - The Manila Times
Can Arcutis' New ZORYVE Clinical Data Transform Treatment Options for Dermatology Patients? - StockTitan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Arcutis Biotherapeutics' (ARQT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arcutis Announces ARQ-154 Program for Seborrheic Dermatitis and Enrollment of First Patient in Phase 2 Proof of Concept Clinical Trial - ACCESS Newswire
FDA accepts sNDA for Arcutis’ Zoryve in young children with eczema - The Pharma Letter
Arcutis: ZORYVE Net Product Revenue Growth Isn't Only Opportunity On Deck (ARQT) - Seeking Alpha
Strong Sales Growth and Financial Stability Drive Buy Rating for Arcutis Biotherapeutics - TipRanks
Mizuho lifts Arcutis stock price target to $21 from $20 By Investing.com - Investing.com Australia
FDA Accepts sNDA for Zoryve Cream for Atopic Dermatitis Treatment in Young Children - Managed Healthcare Executive
Arcutis rises as lead product undergoes FDA review for label expansion - MSN
Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations - Seeking Alpha
Strong Buy Rating for Arcutis Biotherapeutics Driven by Zoryve’s Growth and Market Expansion - TipRanks
Arcutis Biotherapeutics rises on strong sales of skin disease drug - TradingView
Arcutis stock rises on FDA review for Zoryve (ARQT:NASDAQ) - Seeking Alpha
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):